Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis

Molecular and Cellular Biology

Volumn 24, Issue 19, 2004, Pages 8662-8670

  Astrof, Sophie ^a   Crowley, Denise ^a   George, Elizabeth L ^b,e   Fukuda, Tomohiko ^d   Sekiguchi, Kiyotoshi ^d   Hanahan, Douglas ^c   Hynes, Richard O ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OSAKA UNIVERSITY   (Japan)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; FIBRONECTIN; ISOPROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; EMBRYO; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; PROTEIN VARIANT; RETINA NEOVASCULARIZATION; RNA SPLICING; SMOOTH MUSCLE; TRANSGENIC MOUSE;

ALTERNATIVE SPLICING; ANIMALS; EXONS; FIBRONECTINS; ISLETS OF LANGERHANS; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREATIC NEOPLASMS; RETINAL VESSELS; TAIL;

ANIMALIA; MUS MUSCULUS;

EID: 4544299823     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.19.8662-8670.2004     Document Type: Article

References (58)

1. Benjamin, L. E., I. Hemo, and E. Keshet. 1998. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591-1598.
2. Benjamin, L. E., and E. Keshet. 1997. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA 94:8761-8766.
3. Bergers, G., S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Investig. 111:1287-1295.
4. Borsi, L., E. Balza, M. Bestagno, P. Castellani, B. Carnemolla, A. Biro, A. Leprini, J. Sepulveda, O. Burrone, D. Neri, and L. Zardi. 2002. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102:75-85.
5. Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6:389-395.
6. Carnemolla, B., A. Leprini, G. Allemanni, M. Saginati, and L. Zardi. 1992. The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J. Biol. Chem. 267:24689-24692.
7. Carpizo, D., and M. L. Iruela-Arispe. 2000. Endogenous regulators of angiogenesis-emphasis on proteins with thrombospondin-type I motifs. Cancer Metastasis Rev. 19:159-165.
8. Castellani, P., L. Borsi, B. Carnemolla, A. Biro, A. Dorcaratto, G. L. Viale, D. Neri, and L. Zardi. 2002. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol. 161:1695-1700.
9. Castellani, P., G. Viale, A. Dorcaratto, G. Nicolo, J. Kaczmarek, G. Querze, and L. Zardi. 1994. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59:612-618.
10. Clark, E. A., T. R. Golub, E. S. Lander, and R. O. Hynes. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-535.
11. D'Ovidio, M. C., A. Mastracchio, A. Marzullo, M. Ciabatta, B. Pini, S. Uccini, L. Zardi, and L. P. Ruco. 1998. Intratumoral microvessel density and expression of ED-A/ED-B sequences of fibronectin in breast carcinoma. Eur. J. Cancer 34:1081-1085.
12. Egeblad, M., and Z. Werb. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2:161-174.
13. Ferrara, N., J. Lecouter, and R. Lin. 2002. Endocrine gland vascular endothelial growth factor (EG-VEGF) and the hypothesis of tissue-specific regulation of angiogenesis. Endocr. Res. 28:763-764.
14. Ffrench-Constant, C., and R. O. Hynes. 1989. Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo. Development 106:375-388.
15. Folkman, J., K. Watson, D. Ingber, and D. Hanahan. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.
16. Francis, S. E., K. L. Goh, K. Hodivala-Dilke, B. L. Bader, M. Stark, D. Davidson, and R. O. Hynes. 2002. Central roles of α5 β1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler. Thromb. Vasc. Biol. 22:927-933.
17. Fukuda, T., N. Yoshida, Y. Kataoka, R. Manabe, Y. Mizuno-Horikawa, M. Sato, K. Kuriyama, N. Yasui, and K. Sekiguchi. 2002. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. 62:5603-5610.
18. George, E. L., H. S. Baldwin, and R. O. Hynes. 1997. Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 90:3073-3081.
19. George, E. L., and R. O. Hynes. 1994. Gene targeting and generation of mutant mice for studies of cell-extracellular matrix interactions. Methods Enzymol. 245:386-420.
20. Georges-Labouesse, E. N., E. L. George, H. Rayburn, and R. O. Hynes. 1996. Mesodermal development in mouse embryos mutant for fibronectin. Dev. Dyn. 207:145-156.
21. Glukhova, M. A., M. G. Frid, B. V. Shekhonin, Y. V. Balabanov, and V. E. Kotellansky. 1990. Expression of fibronectin variants in vascular and visceral smooth muscle cells in development. Dev. Biol. 141:193-202.
22. Gupta, A. R., N. S. Dejneka, R. J. D'Amato, Z. Yang, N. Syed, A. M. Maguire, and J. Bennett. 2001. Strain-dependent anterior segment neovascularization following intravitreal gene transfer of basic fibroblast growth factor (bFGF). J. Gene Med. 3:252-259.
23. Hamano, Y., M. Zeisberg, H. Sugimoto, J. C. Lively, Y. Maeshima, C. Yang, R. O. Hynes, Z. Werb, A. Sudhakar, and R. Kalluri. 2003. Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin. Cancer Cell 3:589-601.
24. Hanahan, D. 1985. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115-122.
25. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100:57-70.
26. Hirschi, K. K., S. A. Rohovsky, and P. A. D'Amore. 1998. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J. Cell Biol. 141:805-814.
27. Hynes, R. O. 1990. Fibronectins. Springer-Verlag, New York, N.Y.
28. Inoue, M., J. H. Hager, N. Ferrara, H. P. Gerber, and D. Hanahan. 2002. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1:193-202.
29. Inufusa, H., M. Nakamura, T. Adachi, Y. Nakatani, K. Shindo, M. Yasutomi, and H. Matsuura. 1995. Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis. Cancer 75:2802-2808.
30. Jarnagin, W. R., D. C. Rockey, V. E. Koteliansky, S. S. Wang, and D. M. Bissell. 1994. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J. Cell Biol. 127:2037-2048.
31. Kaczmarek, J., P. Castellani, G. Nicolo, B. Spina, G. Allemanni, and L. Zardi. 1994. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer 59:11-16.
32. Kosmehl, H., A. Berndt, S. Strassburger, L. Borsi, P. Rousselle, U. Mandel, P. Hyckel, L. Zardi, and D. Katenkamp. 1999. Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br. J. Cancer 81:1071-1079.
33. Leahy, D. J., I. Aukhil, and H. P. Erickson. 1996. 2.0 A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell 84:155-164.
34. Lohi, J., T. Tani, L. Laitinen, L. Kangas, V. P. Lehto, and I. Virtanen. 1995. Tenascin and fibronectin isoforms in human renal cell carcinomas, renal cell carcinoma cell lines and xenografts in nude mice. Int. J. Cancer 63:442-449.
35. Matsumoto, E., T. Yamada, Y. Kawarada, and T. Sakakuro. 1999. Expression of fibronectin isoforms in human breast tissue: production of extra domain A+/extra domain B+ by cancer cells and extra domain A+ by stromal cell. Jpn. J. Cancer Res. 90:320-325.
36. McCarty, J. H., R. A. Monahan-Earley, L. F. Brown, M. Keller, H. Gerhardt, K. Rubin, M. Shani, H. F. Dvorak, H. Wolburg, B. L. Bader, A. M. Dvorak, and R. O. Hynes. 2002. Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking αv integrins. Mol. Cell. Biol. 22:7667-7677.
37. Morikawa, S., P. Baluk, T. Kaidoh, A. Haskell, R. K. Jain, and D. M. McDonald. 2002. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160:0985-1000.
38. Muro, A. F., A. K. Chauhan, S. Gajovic, A. Iaconcig, F. Porro, G. Stanta, and F. E. Baralle. 2003. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J. Cell Biol. 162:149-160.
39. Ni, H., P. S. Yuen, J. M. Papalia, J. E. Trevithick, T. Sakai, R. Fassler, R. O. Hynes, and D. D. Wagner. 2003. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc. Natl. Acad. Sci. USA 100:2415-2419.
40. Ohnishi, T., S. Hiraga, S. Izumoto, H. Matsumura, Y. Kanemura, N. Arita, and T. Hayakawa. 1998. Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin. Exp. Metastasis 16:729-741.
41. Oyama, F., S. Hirohashi, Y. Shimosato, K. Titani, and K. Sekiguchi. 1989. Deregulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors. J. Biol. Chem. 264:10331-10334.
42. Oyama, F., S. Hirohashi, Y. Shimosato, K. Titani, and K. Sekiguchi. 1990. Oncodevelopmental regulation of the alternative splicing of fibronectin pre-messenger RNA in human lung tissues. Cancer Res. 50:1075-1078.
43. Peters, J. H., G. E. Chen, and R. O. Hynes. 1996. Fibronectin isoform distribution in the mouse. II Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. Cell Adhes. Commun. 4:127-148.
44. Peters, J. H., and R. O. Hynes. 1996. Fibronectin isoform distribution in the mouse. I. The alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the developing mouse embryo. Cell Adhes. Commun. 4:103-125.
45. Peters, J. H., J. E. Trevithick, P. Johnson, and R. O. Hynes. 1995. Expression of the alternatively spliced EIIIB segment of fibronectin. Cell Adhes. Commun. 3:67-89.
46. Pujuguet, P., A. Hammann, M. Moutet, J. L. Samuel, F. Martin, and M. Martin. 1996. Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor-associated myofibroblasts. Am. J. Pathol. 148:579-592.
47. Ramaswamy, S., K. N. Ross, E. S. Lander, and T. R. Golub. 2003. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:49-54.
48. Rodriguez-Manzaneque, J. C., T. F. Lane, M. A. Ortega, R. O. Hynes, J. Lawler, and M. L. Iruela-Arispe. 2001. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 98:12485-12490.
49. Rohan, R. M., A. Fernandez, T. Udagawa, J. Yuan, and R. J. D'Amato. 2000. Genetic heterogeneity of angiogenesis in mice. FASEB J. 14:871-876.
50. Ruchoux, M. M., V. Domenga, P. Brulin, J. Maciazek, S. Limol, E. Tournier-Lasserve, and A. Joutel. 2003. Transgenic mice expressing mutant Notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Am. J. Pathol. 162:329-342.
51. Ruoslahti, E. 2002. Specialization of tumour vasculature. Nat. Rev. Cancer 2:83-90.
52. Scarpino, S., A. Stoppacciaro, C. Pellegrini, A. Marzullo, L. Zardi, F. Tartaglia, G. Viale, and L. P. Ruco. 1999. Expression of EDA/EDB isoforms of fibronectin in papillary carcinoma of the thyroid. J. Pathol. 188:163-167.
53. Serini, G., M. L. Bochaton-Piallat, P. Ropraz, A. Geinoz, L. Borsi, L. Zardi, and G. Gabbiani. 1998. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1. J. Cell Biol. 142:873-881.
54. Smith, L. E., E. Wesolowski, A. McLellan, S. K. Kostyk, R. D'Amato, R Sullivan, and P. A. D'Amore. 1994. Oxygen-induced retinopathy in the mouse. Investig. Ophthalmol. Vis. Sci. 35:101-111.
55. Takasaki, I., A. V. Chobanian, W. S. Mamuya, and P. Brecher. 1992. Hypertension induces alternatively spliced forms of fibronectin in rat aorta. Hypertension 20:20-25.
56. Takasaki, I., A. V. Chobanian, R. Sarzani, and P. Brecher. 1990. Effect of hypertension on fibronectin expression in the rat aorta. J. Biol. Chem. 265:21935-21939.
57. Tan, M. H., Z. Sun, S. L. Opitz, T. E. Schmidt, J. H. Peters, and E. L. George. 2004. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 104:11-18.
58. Tarli, L., E. Balza, F. Viti, L. Borsi, P. Castellani, D. Berndorff, L. Dinkelborg, D. Neri, and L. Zardi. 1999. A high-affinity human antibody that targets tumoral blood vessels. Blood 94:192-198.